Despite falling short of goals in a Phase II trial, Neuraltus Pharmaceuticals saw enough evidence of efficacy in Lou Gehrig's disease patients on its experimental drug to push forward plans for a late-state study. Its decision to start the Phase III program next year underscores the critical need for new therapies against the muscle-disabling disorder.
In this case the object of their desperation is NP001, an experimental drug now in a Phase II study.
A small Palo Alto, CA-based biotech has garnered some fresh attention for itself after touting the results of a small Phase I study designed to test its lead drug by measuring its impact on a key...
Neuraltus Pharmaceuticals, a biotech developing small molecule drugs for neurodegenerative diseases, has wrapped a $17 million Series A round. Co-investing in the Series A funding are Latterell